Inactive Instrument

Highlights Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jun. 03	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000	CI
Jun. 03	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	May. 30	MT
Sector Update: Health Care	May. 30	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Inflation Data	May. 30	MT
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	May. 30	MT
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	May. 02	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	May. 01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	May. 01	MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	May. 01	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	Feb. 28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Prices for new US drugs rose 35% in 2023, more than the previous year	Feb. 23	RE
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data	Feb. 16	MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval	Feb. 16	RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication	Feb. 16	CI
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

Highlights

Filters